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Disorders of Erythropoiesis
Molecular characterization of five Portuguese
patients with pyrimidine 5’-nucleotidase deficient
hemolytic anemia showing three new P5’N-I
mutations
Four different gene mutations were identified in
five unrelated Portuguese patients with pyrimidine
5’-nucleotidase type I (P5’N-I) deficient chronic
hemolytic anemia. Mutations 502G→C (168
Gly→Arg), 773T→C (258Ile→Thr) and the inser-
tion of an Alu element in exon 9, leading to skip-
ping of this exon in the mRNA transcript, are
newly described mutations whereas mutation
425T→C (142Leu→Pro) has been previously
reported.haematologica 2006; 91:266-267
(http://www.haematologica.org/journal/2006/02/266.html)
Pyrimidine 5’-nucleotidase type-I isoform (P5’N-I) is
essential for the catabolism of pyrimidine nucleotides. The
enzyme preferentially hydrolyzes uridine monophosphate
(UMP) and cytidine monophosphate (CMP), which result
from RNA degradation during reticulocyte maturation.1
P5’N-I deficiency (OMIM*606224) causes chronic non-
spherocytic hemolytic anemia associated with accumula-
tion of pyrimidine nucleotides within erythrocytes, and
marked basophilic stippling on peripheral blood smears.1
The specific diagnosis depends on demonstration of high
concentrations of pyrimidine nucleotides in erythrocytes
and severe reduction in P5’N-I activity.1,2 The P5’N-I gene
(NT5C3) is localized on chromosome 7p15, and was first
reported to have ten exons coding for two alternatively
spliced mRNA forms.3 Recently, a third spliced form was
identified, raising the total number of exons to 11 (1-2-R-
3 to 10).4 Molecular characterization of affected patients
has so far identified 15 different P5’N-I gene mutations,
most of them within exons 8 and 9.3-7
In this report we present the molecular characteriza-
tion of five patients of Portuguese ancestry with P5’N-I
deficient chronic hemolytic anemia (Table 1). The diag-
nosis was based on clinical data, marked basophilic stip-
pling, anemia with increased number of reticulocytes, a
decreased purine-pyrimidine nucleotide ratio (<2.29),
and demonstration of the absence of functional P5’N-I
protein in hemolysates by electrophoretic analysis
(Figure 1A). The age of these patients at diagnosis ranged
from 3 to 74 years. All patients are the result of known
consanguineous marriages, or have ancestries from
neighboring villages; we could not establish any relation-
ship between the five patients. Routine hematologic
parameters were determined by standard procedures.8
The purine-pyrimidine nucleotide ratio was calculated
using previously published methods.8 Electrophoretic
analysis was performed as reported elsewhere.9 
After informed consent, peripheral blood was collected
from patients, families and unrelated healthy individuals
from central Portugal. Genomic DNA was extracted
using standard methodologies. The entire coding
sequence and regions adjacent to the P5’N-I gene were
amplified by polymerase chain reaction using specific
oligonucleotides.5 Exons 7, 8 and 9 were sequenced with
the automatic genetic analyzer ABI-Prism 310. The
remaining exons were screened by single strand confor-
Table 1. Hematologic, biochemical and molecular data of five
Portuguese patients with P5’N-I deficiency.
Patient Sex Age Hb Pur:Pyr Retics P5’N-I Effect
(Yr) (g/L) (OD260/OD280) (% of RBC) mutation
1 M 21 125 1.20 10 502G→C 168Gly→Arg
2 M 18 114 1.20 10 773T→C 258Ile→Thr
3 M 77 88 1.34 7 Alu ins Exon 9 skipping
4 M 5 106 1.20 10 Alu ins Exon 9 skipping
5 M 53 114 1.08 25 425T→C 142Leu→Pro
Hb: hemoglobin (normal values: adult males 135-170 g/L; 2-9 years 115-145
g/L); Pur:Pyr: purine-pyrimidine nucleotide ratio (normal values = 2.29 or
higher); Retics – reticulocytes (normal value < 2% of RBC).
Figure 1. A. Analysis of P5’N-I activity after starch gel electrophore-
sis of fresh hemolysates from two controls and P5’N-I deficient
patient n. 5. The substrate used was UMP. All the five Portuguese
patients showed the same electrophoretic pattern as patient n. 5.
Lanes 1 and 3 – normal subjects; lane 2 – patient n. 5. B. Genomic
DNA amplification of P5’N-I exon 9. Agarose gel electrophoresis
shows polymerase chain reaction fragments with 636 bp in
patients n. 3 and 4 instead of the normal 306 bp fragment. Lane
1, DNA size markers (100 bp ladder); lane 2, patient n. 3; lane 3,
patient n. 4; lane 4, normal subject. C. Reverse transcription poly-
merase chain reaction (RT-PCR) analysis of the insertional muta-
tion. To evaluate the effect of the P5’N-I Alu insertion we used the
RT-PCR method to generate fragments spanning exons 8 to 10.
Agarose gel electrophoresis of RT-PCR products from patient n. 3
shows a faster moving band (290 bp) relative to that of normal
controls (491 bp). Lane 1, DNA size markers (pBR322 digested
with HinfI); lane 2 - patient n. 3; lane 3 - normal subject. 
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mational polymerase analysis. Poly(A) mRNA was isolat-
ed from reticulocytes of patient 3 and from two control
individuals, using the MicroPoly(A)Pure Kit (Ambion).
Purified mRNA (10-50 µg) was reverse transcribed (RT)
into cDNA using the First-Strand cDNA Synthesis Kit
(Amersham Biosciences); a fragment spanning exons 8 to
10 [oligonucleotides: 5’-aagttggtgtccaatttatg-3’ (forward)
and 5’-gtcaatgcattcaccatatc-3’ (reverse)] was amplified
and sequenced. 
Patient n. 1 showed a previously undescribed mutation
in exon 8, the transversion 502G→C, predicting the
amino acid change 168Gly→Arg. This is a drastic non-
conservative substitution of a flexible amino acid
(glycine) by a polar positive residue with a large dissimi-
lar side chain (arginine), increasing the overall rigidity of
the polypeptide in this specific region. Gly168 is con-
served from C. elegans to humans, and falls in a highly
conserved region of 7 residues,3 an area likely to be of
functional and/or structural importance
Patient n. 2 has a new mutation in exon 9, the transi-
tion 773T→C, predicting the replacement of the aliphat-
ic non-polar amino acid isoleucine, in position 258, by
the uncharged polar threonine (258Ile→Thr). The evolu-
tionary conservation of Ile258 from D. melanogaster to
humans3 may indicate that this residue has important
functional and/or structural features. 
In patients n. 3 and 4 amplification of exon 9 (Figure
1B) and sequencing revealed the insertion of a 330 bp Alu
repetitive element between nucleotides 743-744. The
P5’N Alu element is closely related to the AluYa5 and
AluYa1 subfamilies (98% identity). Sequence analysis of
reverse-transcriped polymerase chain reaction products
from patient n. 3 spanning exons 8 to 10 (Figure 1C)
showed a normal nucleotide sequence corresponding to
exons 8 and 10, lacking the in-between exon 9. Predicted
translation of the abnormal mRNA results in a polypep-
tide lacking the 67 amino acids encoded by exon 9,
which certainly affects the P5’N-I enzymatic activity. It is
the first time that a P5’N chronic hemolytic anemia has
been associated with an Alu insertion.
Patient n. 5 was found to have a missense mutation in
exon 7, 425T→C (142Leu→Pro), which has been previ-
ously reported in a Japanese patient4 Chiarelli et al.,10
studying the biochemical properties of the recombinant
protein, showed that it was extremely unstable and sug-
gested that the L142P substitution was the cause of the
polypeptide’s increased susceptibility to proteolysis.
The three point mutations 502G→C, 773T→C and
425T→C were confirmed by restriction enzyme analysis
with BstUI, BseNI and SmlI, respectively. No other muta-
tions were found in the remaining P5’N-I gene coding
regions or exon/intron junctions, and screening of 60
normal control individuals was negative for the new
P5’N-I mutations. All the patients have their mutations in
the homozygous state, in concordance with the genetic
profile for the disease in other populations.
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